The median time to ILD/pneumonitis onset was 5.5 months (range, <0.1-46.8 months) among patients with all tumor types and doses and 5.6 months (range, 1.1-20.8 months) among patients with HER2-positive metastatic breast cancer receiving 5.4 mg/kg every 3 weeks.60 Here, ERBB2 is linked to neoplasm.